Boston, MA 04\/12\/2013 (wallstreetpr) – A biotechnology company ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) (Current: $12.83, Down by 2.14%), which has annual sales of $5 million ascended by 43 percent after it said that its lead drug will gain U.S regulatory review prior to its anticipated time. Through yesterday, its shares rose five-fold in 12 months. By the end of 2014, the San Diego-based company plans on applying for a review by the Food and Drug Administration of its drug pimavanserin. Later this month, a final-phase trial was to be conducted. The company said that the FDA has agreed that Acadia will not have to conduct that particular trial.<\/p>\n
Speedier trial<\/strong> Progressive deterioration<\/strong> Boston, MA 04\/12\/2013 (wallstreetpr) – A biotechnology company ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) (Current: $12.83, Down by 2.14%), which has annual sales of $5 million ascended […]<\/p>\n","protected":false},"author":32,"featured_media":6073,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2013,2014],"stock_ticker":[],"class_list":["post-6072","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-acadia-pharmaceuticals-inc-nasdaqacad","tag-nasdaqacad","entry"],"acf":[],"yoast_head":"\n
\nPimavanserin is to be used for the treatment of Parkinson\u2019s disease psychosis. Instead of the scheduled review, Acadia can now use supportive data and trial results from the various other studies that have been conducted and then seek a review of the drug. In a statement, the Chief Executive Officer of the company, Uli Hacksell said that the company is very pleased with the way the talks with the Food Drug Administration authorities progressed and the outcome has been very conducive to the company as well. This will go a long way in reducing the time and the costs associated with the PDP development program.<\/p>\n
\nParkinson\u2019s disease or PD is a chronic in nature. The disorder has progressive movement. This means that the symptoms not only continue but tend to worsen over a period of time. Over one million people in the U.S suffer from the disease that has no solid cure as of now and its symptoms are largely managed with medication. Acadia\u2019s once-a-day pill primavanserin is under trial. The study that is being conducted is for the treatment of loss of contact with the real world and more often than not is accompanied by hallucinations.<\/p>\n","protected":false},"excerpt":{"rendered":"